

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number
WO 2005/021530 A1

(51) International Patent Classification⁷: **C07D 401/12**,
A61K 31/47

(21) International Application Number:
PCT/EP2004/009724

(22) International Filing Date: 26 August 2004 (26.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0320320.5 29 August 2003 (29.08.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JOHNSON, Christopher, Norbert** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **MOSS, Stephen, Frederick** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **TAIT, Malcolm, M** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **WITTY, David, R** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB).

(74) Agent: **GIBSON, Mark**; GlaxoSmithKline (CIP-CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 8- (1-PIPERAZINYL)- QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS

(57) Abstract: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.


WO 2005/021530 A1

8- (1-PIPERAZINYL)-QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS

This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

JP 02262627 (Japan Synthetic Rubber Co) describes a series of substituted quinoline derivatives useful as wavelength converting elements. WO 00/42026 (Novo Nordisk) describes a series of quinoline and quinoxaline compounds for use as GLP-1 agonists.

A structurally novel class of compounds has now been found which also possess affinity for the 5-HT₆ receptor. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

- R¹ represents hydrogen, C₁₋₆ alkyl, -C₀₋₄ alkyl-C₃₋₈cycloalkyl, -C₁₋₄ alkyl-aryl, -C₁₋₄ alkyl-heteroaryl or -C₀₋₄ alkyl-heterocyclyl;
 wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R¹ may be optionally substituted by one or more (eg. 1, 2 or 3) halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl groups;
 R² represents hydrogen or C₁₋₆ alkyl;
 m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R² groups may instead be linked to form a CH₂, (CH₂)₂ or (CH₂)₃ group;
 when R¹ represents C₁₋₆ alkyl, R¹ may optionally be linked to R² to form a group (CH₂)₂, (CH₂)₃ or (CH₂)₄;
 R³, R⁴ and R⁵ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;
 R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or R⁶ and R⁷ together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;
 n represents an integer from 1 to 3;

p represents 1 or 2;

R^a represents hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₇cycloalkyl or -C₁₋₃alkyl-C₃₋₇cycloalkyl;

R^b represents hydrogen, C₁₋₆alkyl, -C₀₋₄alkyl-aryl or -C₀₋₄alkyl-heteroaryl;

or R^a and R^b together with the nitrogen atom to which they are attached may form a

5 nitrogen containing heterocyclyl group;

wherein said aryl, heteroaryl or heterocyclyl groups of R^a and R^b may be optionally

substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, trifluoromethanesulfonyloxy,

10 pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group
15 CONR⁸R⁹ or SO₂NR⁸R⁹, wherein R⁸ and R⁹ independently represent hydrogen or C₁₋₆ alkyl or R⁸ and R⁹ together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;
or solvates thereof.

20

Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C₁₋₄ alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine,
25 bromine or iodine.

The term "aryl" includes single and fused rings wherein at least one ring is aromatic, for example, phenyl, naphthyl and tetrahydronaphthalenyl.

30 The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-10 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl.
35 Suitable examples of such fused aromatic rings include benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like. Heteroaryl groups, as described above, may be linked to the remainder of the
40 molecule via a carbon atom or, when present, a suitable nitrogen atom except where otherwise indicated above.

The term "nitrogen containing heteroaryl" is intended to represent any heteroaryl group as defined above which contains a nitrogen atom.

5 The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring or a 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring containing 1 to 3 heteroatoms selected from oxygen or nitrogen fused to a benzene or monocyclic heteroaryl ring. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, diazepanyl, azepanyl, dihydroimidazolyl, tetrahydropyranyl, 10 tetrahydrothiapyranyl and tetrahydrofuranyl. Suitable examples of benzofused heterocyclic rings include dihydroindolyl, dihydroisoindolyl, tetrahydroquinolyl, tetrahydrobenzazepinyl and tetrahydroisoquinolyl.

15 The term "nitrogen containing heterocyclyl" is intended to represent any heterocyclyl group as defined above which contains a nitrogen atom.

Preferably, R¹ represents hydrogen, methyl, ethyl, isopropyl, isobutyl or 2,2-dimethylpropyl.

More preferably, R¹ represents hydrogen or methyl, especially hydrogen.

20 Preferably R² represents hydrogen, methyl (eg. 3-methyl, 2-methyl, 3,3-dimethyl or 2,5-dimethyl) or is linked to R¹ to form a (CH₂)₃ group.

Preferably, m and p independently represent 1 or 2, more preferably m and p both represent 1.

More preferably R² represents hydrogen or methyl (e.g. 3-methyl), especially hydrogen.

25 Preferably R³ represents hydrogen, methyl (eg. 6-methyl) or halogen (eg. 7-chloro).

Preferably n represents 1.

More preferably, R³ represents hydrogen.

Preferably R⁴ and R⁵ independently represent hydrogen or methyl, especially hydrogen.

30 In one preferred embodiment, m represents 2 and both R² groups are linked to form a CH₂ group linking C-2 and C-5 of the piperazine ring.

Preferably, R^a and R^b together with the nitrogen atom to which they are attached form a nitrogen containing heterocyclyl group (eg. 1-piperidinyl, 4-morpholinyl, 1-(2,3-dihydro-1*H*-indolyl) or 2-(2,3-dihydro-1*H*-isoindolyl)) optionally substituted by a halogen atom (eg. fluorine). More preferably, R^a and R^b together with the nitrogen atom to which they 35 are attached form 1-(2,3-dihydro-1*H*-indolyl).

Preferred compounds according to the invention include examples E1-E5 as shown below, or a pharmaceutically acceptable salt thereof.

40 The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be


apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, **66**, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvated, eg. as the hydrate. This invention includes within its scope stoichiometric solvates (eg. hydrates) as well as compounds containing variable amounts of solvent (eg. water).


Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)




with a compound of formula (III)




wherein R¹ᵃ is as defined for R¹ or an N-protecting group, R², R³, R⁴, R⁵, Rᵃ, Rᵇ, m, n and p are as defined above and L¹ represents a suitable leaving group, such as a halogen atom (e.g. a bromine or iodine atom) or a trifluoromethylsulfonyloxy group, and

thereafter as necessary removing an R^{1a} N-protecting group. The N-protecting group used may be any conventional group e.g. *t*-butoxycarbonyl (Boc) or benzyloxycarbonyl. Further N-protecting groups which may be used include methyl; or

- 5 (b) reacting a compound of formula (IV)



with a compound of formula (V)



10

wherein R^{1a} is as defined for R^1 or an N-protecting group, R^2 , R^3 , R^4 , R^5 , R^a , R^b , m , n and p are as defined above, and L^2 represents a suitable leaving group, such as a halogen atom and thereafter as necessary removing an R^{1a} N-protecting group;

- 15 (c) deprotecting a compound of formula (I) which is protected; and thereafter optionally

(d) interconversion to other compounds of formula (I) and/or forming a pharmaceutically acceptable salt and/or solvate.

20

Process (a) may be performed in the presence of a palladium, nickel or copper catalyst, for example a mixture of a palladium source such as $Pd_2(dba)_3$ and a suitable ligand such as (R)-, (S)- or (\pm)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) or (2-dicyclohexylphosphanylphenyl)-dimethylamine or 1,1'-bis-diphenylphosphinoferrocene, together with a suitable base such as sodium *t*-butoxide, in an inert solvent such as 1,4-dioxane.

25

Process (b) may be performed in the presence of a suitable base, such as sodium carbonate using a suitable solvent such as *n*-butanol.

30

In processes (a), (b) and (c) examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or *t*-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such


35

as hydrochloric acid) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl (-COCF₃) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid. A further amine protecting group includes methyl which may be removed using standard methods for N-dealkylation (e.g. 1-chloroethyl chloroformate under basic conditions followed by treatment with methanol).

Process (d) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, reductive alkylation, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, N-dealkylation of a compound of formula (I) wherein R¹ represents an alkyl group to give a compound of formula (I) wherein R¹ represents hydrogen. It will be appreciated that such interconversion may be interconversion of protected derivatives of formula (I) which may subsequently be deprotected following interconversion.


In addition, process (d) may comprise, for example, reacting a compound of formula (I), wherein R¹ represents hydrogen, with an aldehyde or ketone in the presence of a reducing agent in order to generate a compound of formula (I) where R¹ represents C₁₋₆ alkyl, -C₀₋₄ alkyl-C₃₋₈cycloalkyl, -C₁₋₄ alkyl-aryl, -C₁₋₄ alkyl-heteroaryl or -C₀₋₄ alkyl-heterocyclyl. This may be performed using a hydride donor agent such as sodium cyanoborohydride, sodium triacetoxyborohydride or a resin bound form of cyanoborohydride in an alcoholic solvent such as ethanol and in the presence of an acid such as acetic acid, or under conditions of catalytic hydrogenation. Alternatively, such a transformation may be carried out by reacting a compound of formula (I), wherein R¹ represents hydrogen, with a compound of formula R¹-L, wherein R¹ represents C₁₋₆ alkyl, -C₀₋₄ alkyl-C₃₋₈cycloalkyl, -C₁₋₄ alkyl-aryl, -C₁₋₄ alkyl-heteroaryl or -C₀₋₄ alkyl-heterocyclyl and L represents a leaving group such as a halogen atom (e.g. bromine or iodine) or methylsulfonyloxy group, optionally in the presence of a suitable base such as potassium carbonate, sodium hydride or triethylamine using an appropriate solvent such as N,N-dimethylformamide, tetrahydrofuran or a C₁₋₄alkanol.

Compounds of formula (II) may be prepared by reacting a compound of formula (VI)



wherein R^3 , R^4 , R^5 , n , and L^1 are as defined above and L^3 represents a suitable leaving group such as halogen, e.g. fluorine or chlorine; with a compound of formula NHR^aR^b wherein R^a and R^b are as defined above. Such a reaction may advantageously be carried out in an inert solvent such as dichloromethane in the presence of a base such as triethylamine or an excess of the compound of formula NHR^aR^b .

Compounds of formula (VI) may be prepared in accordance with the following scheme:



wherein R^3 , R^4 , R^5 , n , L^1 and L^3 are as defined above and L^4 represents a suitable leaving group such as halogen (e.g. bromine or iodine), preferably L^1 and L^4 represent different leaving groups (e.g. L^1 and L^4 represent chlorine and iodine, respectively).


Step (i) typically comprises addition of a sulfur nucleophile using a suitable metal salt of a dialkyldithiocarbamic acid (e.g. zinc dimethyldithiocarbamate) in the presence of a suitable copper (I) salt (e.g. copper triflate) and a suitable ligand such as 1,2-dimethylaminoethane in an appropriate solvent such as dimethylsulfoxide at an elevated temperature (e.g. 90 °C).

Step (ii) typically comprises cleavage of the thiocarbamoyl moiety using a suitable nucleophile, such as sodium sulfide in an appropriate solvent, such as aqueous methanol.

Step (iii) typically comprises oxidation to the disulfide using an oxidant, such as iodine and such a process may be advantageously carried out in a biphasic reaction medium, such as aqueous potassium monohydrogenphosphate and dichloromethane.

Step (iv) typically comprises an oxidation with concomitant introduction of the group L^3 . When L^3 represents a chlorine atom this process may be advantageously carried out using sulfonyl chloride in the presence of an oxidant, such as potassium nitrate in an inert solvent, such as acetonitrile.

Compounds of formula (VII) where L^4 represents halogen may be prepared by reaction of a compound of formula (XI)




(XI)

5

wherein R^3 , R^4 , R^5 , n , and L^1 are as defined above, with an appropriate halogenating reagent. For example, when L^4 represents an iodine atom, an appropriate process comprises reaction of a compound of formula (XI) with N-iodosuccinimide in the presence of acetic acid at elevated temperature (e.g. 80 °C). Such a reaction may be

10

Compounds of formula (IV) may be prepared in accordance with the following scheme:



wherein R^3 , R^4 , R^5 , n , R^a and R^b are as defined above, L^5 represents a suitable leaving

group such as a halogen atom (eg. bromine or iodine) and L^6 represents a suitable leaving group such as a halogen atom (eg. fluorine or chlorine).

5 Step (i) typically comprises addition of a sulfur nucleophile using a suitable metal salt of a dialkyldithiocarbamic acid (e.g. zinc dimethyldithiocarbamate) in the presence of a suitable copper (I) salt (e.g. copper triflate) and a suitable ligand such as 1,2-dimethylaminoethane in an appropriate solvent such as dimethylsulfoxide at an elevated temperature (e.g. 90 °C).

10 Step (ii) typically comprises cleavage of the thiocarbamoyl moiety using a suitable nucleophile, such as sodium sulfide or trimethylsilanol sodium salt, in an appropriate solvent such as aqueous methanol or dimethyl sulfoxide respectively.

15 Step (iii) typically comprises oxidation to the disulfide using an oxidant, such as iodine and such a process may be advantageously carried out in a biphasic reaction medium, such as aqueous potassium monohydrogenphosphate and dichloromethane.

20 Step (iv) typically comprises an oxidation with concomitant introduction of the group L^6 . When L^6 represents a chlorine atom this process may be advantageously carried out using sulfuryl chloride in the presence of an oxidant, such as potassium nitrate in an inert solvent, such as acetonitrile.

25 Step (v) typically comprises addition of a compound of formula NHR^aR^b wherein R^a and R^b are as defined above, using a procedure analogous to that used to prepare compounds of formula (II) from compounds of formula (VI).

30 Step (vi) typically comprises reduction of the nitro group using a suitable reducing agent, e.g. iron powder in acetic acid or aqueous titanium trichloride in appropriate organic solvent such as tetrahydrofuran.

35 An alternative process for the preparation of compounds of formula (II) as defined above where L^1 represents halogen comprises diazotisation of a compound of formula (IV) as defined above using standard methods (e.g. use of sodium nitrite and an appropriate acid) followed by treatment of the resulting diazonium salt with an appropriate reagent for the introduction of the halogen (e.g. a copper (I) halide such as copper (I) bromide, or potassium iodide).

40 Compounds of formula (III), (V), (XI) and (XII) are known in the literature or can be prepared by analogous methods.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for the 5-HT₆ receptor and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders (e.g. Alzheimers disease, age related cognitive decline and mild cognitive impairment), Parkinsons Disease, ADHD (Attention Deficit Disorder/Hyperactivity Syndrome), sleep disorders (including disturbances of Circadian rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia (in particular cognitive deficits of schizophrenia), stroke and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome). Compounds of the invention are also expected to be of use in the treatment of obesity.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders. In particular the invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders.

5-HT₆ antagonists have the potential to be capable of increasing basal and learning-induced polysialylated neuron cell frequency in brain regions such as the rat medial temporal lobe and associated hippocampus, as described in WO 03/066056. Thus, according to a further aspect of the present invention, we provide a method of promoting neuronal growth within the central nervous system of a mammal which comprises the step of administering a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.

The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable
10 compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to
15 methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations
20 may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound
25 of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering
30 agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene
35 oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60%
40 by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer,

and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 200 mg, for example 20 to 40 mg; and such unit doses will preferably be administered once a day, although administration more than once a day may be required; and such therapy may extend for a number of weeks or months.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

15 Description 1

8-Chloro-3-iodoquinoline (D1)

N-Iodosuccinimide (67.9 g, 0.30 mmol) was added in portions to a stirred solution of 8-chloroquinoline (49 g, 0.30 mmol) (*J. Org. Chem.*, 1987, **52**, 1673-80) in acetic acid (300 ml) at 70 °C under argon. The mixture was heated to 70 °C for 18 h and then concentrated *in vacuo*. The residue was redissolved in dichloromethane (600 ml) and the solution was washed successively with 10% aqueous sodium thiosulfate solution (2 x 300 ml) and 10% aqueous sodium hydrogen carbonate solution (2 x 300 ml), dried (MgSO₄) and concentrated *in vacuo* to a solid. The solid was recrystallised from ethyl acetate to afford the title compound (D1) as a yellow solid (42 g, 0.145 mol, 48%). The residue from recrystallisation was purified by chromatography over silica gel eluting with a toluene/acetone gradient to afford a second crop of the product (18 g, total yield 69%).
 δ_{H} (CDCl₃) 7.49 (1H, t, J = 8.1Hz), 7.65 (1H, dd, J = 1.4Hz, 8.3Hz), 7.85 (1H, dd, J = 1.3Hz, 7.4Hz), 8.57 (1H, d, J = 2.1Hz), 9.15 (1H, d J = 2.1Hz).
Mass Spectrum: C₉H₅ClIN requires 289, 291; found 290, 292 (MH⁺)

20 Description 2

8-Chloro-3-quinolinyl dimethyldithiocarbamate (D2)

N, N'-Dimethylethylene diamine (0.15 g, 1.7 mmol) was added to a stirred mixture of dimethyldithiocarbamic acid zinc salt (5.8 g, 19.0 mmol), copper (I) triflate (0.44 g, 0.9 mmol) and 8-chloro-3-iodoquinoline (D1) (5 g, 19.0 mmol) in dimethyl sulfoxide (25 ml). This mixture was heated to 90 °C for 3 h, then cooled to ambient temperature, diluted with dichloromethane (100 ml), stirred with activated charcoal (1 g) and filtered. The filtrate was washed with water (2 x 200 ml), dried (MgSO₄) and concentrated *in vacuo* to give the title compound (D2) as a solid in crude form (5.3 g, 19 mmol, 100%) which was used directly in the next stage (see D3).
 δ_{H} (CDCl₃) 3.57 (6H, s), 7.52 (1H, t, J = 7.8Hz), 7.76 (1H, dd, J = 1.3Hz, 8.2Hz), 7.90 (1H, dd, J = 1.3Hz, 7.5Hz), 8.28 (1H, d, J = 2.1Hz), 8.95 (1H, d, J = 2.1Hz).

Mass Spectrum: $C_{12}H_{11}ClN_2S_2$ requires 282, 284; found 283, 285 (MH^+)

Description 3

8-Chloro-3-quinolinethiol (D3)

- 5 A solution of sodium sulfide (1.27 g, 5.3 mmol) in water (7 ml) was added to a stirred suspension of 8-chloro-3-quinolinyl dimethyldithiocarbamate (D2) (0.5 g, 1.8 mmol) in methanol (7 ml) and 1,4-dioxan (7 ml) at ambient temperature under argon. The suspension was heated at 60 °C for 18 h then at 80 °C for 1 h. The reaction mixture was cooled and poured into a 5% aqueous solution of citric acid (100 ml) and the whole
10 was extracted with dichloromethane (3 x 100 ml). The combined organic extracts were dried ($MgSO_4$) and concentrated *in vacuo* to afford the title compound (D3) in crude form as a solid (0.24 g, 1.2 mmol, 70%) which was used directly in the next stage (see D4).
Mass Spectrum: C_9H_6ClNS requires 195, 197; found 196, 198 (MH^+)

15 Description 4

3,3'-Dithiobis(8-chloroquinoline) (D4)

- A 10% aqueous solution of potassium hydrogen phosphate (50 ml) and a solution of 8-chloro-3-quinolinethiol (D3) (3.2 g, 16.1 mmol) in dichloromethane (50 ml) was treated with iodine (4.1 g, 16.1 mmol). The mixture was vigorously stirred at ambient
20 temperature for 1.5 h, then was diluted with dichloromethane (300 ml), vigorously shaken and the layers separated. The organic extract was dried ($MgSO_4$) and concentrated to a solid residue. A solution of this residue in ethyl acetate was pre-adsorbed onto silica gel and purified by chromatography on silica gel eluting with an ethyl acetate/hexane gradient to afford the title compound (D4) as a solid (2.1 g, 5.3
25 mmol, 67%).
 δ_H ($CDCl_3$) 7.48 (1H, t, J = 8.2Hz), 7.65 (1H, dd, J = 1.3Hz, 8.3Hz), 7.83 (1H, dd, J = 1.3Hz, 7.5Hz), 8.26 (1H, d, J = 2.3Hz), 9.11 (1H, d, J = 2.3Hz).
Mass Spectrum: $C_{18}H_{10}Cl_2N_2S_2$ requires 388, 390; found 389, 391 (MH^+)

30 Description 5

8-Chloro-3-quinolinesulfonyl chloride (D5)

- Potassium nitrate (2.46 g, 24.3 mmol) was added portionwise to a stirred suspension of the 3,3'-dithiobis(8-chloroquinoline) (D4) (1.9 g, 4.9 mmol) in acetonitrile (50 ml) at 0 – 5 °C. To this mixture was then added sulfuryl chloride (2.3 ml, 24.3 mmol) dropwise over
35 0.3 h and the temperature was maintained for 1 h. To the cold reaction mixture was then added a cold saturated aqueous solution of sodium carbonate (45 ml) and the whole was quickly extracted with diethyl ether (3 x 100 ml). The combined extracts were dried ($MgSO_4$) and concentrated *in vacuo* to give the title compound (D5) as a solid (1.3 g, 5.0 mmol, 51%).
40 δ_H ($CDCl_3$) 7.71 (1H, t, J = 8.0Hz), 8.00 (1H, dd, J = 1.3Hz, 8.2Hz), 8.11 (1H, dd, J = 1.3Hz, 7.5Hz), 8.90 (1H, d, J = 2.3Hz), 9.51 (1H, d, J = 2.3Hz).
Mass Spectrum: $C_9H_5Cl_2NO_2S$ requires 261, 263; found 262, 264 (MH^+)

Description 6**8-Chloro-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)quinoline (D6)**

To a stirred solution of 8-chloro-3-quinolinesulfonyl chloride (D5) (0.63 g, 2.4 mmol) in dichloromethane (10 ml) was added 2,3-dihydro-1H-indole (0.32 g, 2.6 mmol) and triethylamine (0.37 ml, 2.6 mmol) at 0 – 5°C under argon. After 1 h at this temperature range, the mixture was warmed to ambient temperature and stirred for 18 h. The reaction mixture was washed with water (2 x 15 ml), dried (MgSO₄) and concentrated *in vacuo* to an oil. The oil was purified by chromatography over silica gel eluting with a gradient of ethyl acetate/hexane to afford the title compound (D6) as a solid (0.62 g, 1.8 mmol, 75%).

δ_H (CDCl₃) 2.93 (2H, t, J = 8.4Hz), 4.02 (2H, t, J = 8.4Hz), 6.96-7.09 (2H, m), 7.19-7.26 (2H, m), 7.59 (1H, t, 8.0Hz), 7.72 (1H, d, J = 8.1Hz), 7.85 (1H, dd, J = 1.3Hz, 8.2Hz), 7.97 (1H, dd, J = 1.3Hz, 7.5Hz), 8.66 (1H, d, J = 2.2Hz), 9.27 (1H, d, J = 2.2Hz).
Mass Spectrum: C₁₇H₁₃ClN₂O₂S requires 344, 346; found 345, 347 (MH⁺)

Description 7**8-Chloro-3-[(5-fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]quinoline (D7)**

To a stirred solution of 8-chloro-3-quinolinesulfonyl chloride (D5) (0.63 g, 2.4 mmol) in dichloromethane (10 ml) was added 2,3-dihydro-1H-isoindole hydrochloride (0.46 g, 2.6 mmol) and triethylamine (0.74 ml, 5.3 mmol) at 0 – 5°C under argon. After 1 h at this temperature range, the mixture was warmed to ambient temperature and stirred for 18 h. The precipitated solid was filtered off and purified by chromatography over silica gel eluting with a gradient of ethyl acetate/hexane to afford the title compound (D7) as a solid (0.48 g, 1.3 mmol, 54%).

Mass Spectrum: C₁₇H₁₂ClFN₂O₂S requires 362, 364; found 363, 365 (MH⁺)

Description 8**8-Chloro-3-(1-piperidinylsulfonyl)quinoline (D8)**

To a stirred solution of 8-chloro-3-quinolinesulfonyl chloride (D5) (0.4 g, 1.5 mmol) in dichloromethane (10 ml) was added piperidine (0.45 ml, 4.6 mmol) at 0 – 5°C under argon. After 1 h at this temperature range, the mixture was warmed to ambient temperature and stirred for 18 h. The solution was washed with water (2 x 15 ml), dried (MgSO₄) and concentrated *in vacuo* to give the title compound (D8) as a solid (0.297g, 1.0 mmol, 64%).

Mass Spectrum: C₁₄H₁₅ClN₂O₂S requires 310, 312; found 311, 313 (MH⁺)

Description 9**8-Chloro-3-(4-morpholinylsulfonyl)quinoline (D9)**

The title compound (D9) was prepared in 53% yield by a similar method to that of Description 8 using morpholine in place of piperidine.

Mass Spectrum: C₁₃H₁₃ClN₂O₃S requires 312, 314; found 313, 315 (MH⁺)

Description 10**1,1-Dimethylethyl 4-[3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-8-quinoliny]-1-piperazinecarboxylate (D10)**

- 5 A stirred suspension of 8-chloro-3-(2,3-dihydro-1H-indol-1-ylsulfonyl)quinoline (D6)(0.26 g, 0.74 mmol), 1,1-dimethylethyl 1-piperazinecarboxylate (0.152g, 0.81 mmol), tris(dibenzylideneacetone)dipalladium (0) (0.02 g, 0.022 mmol), 2-dicyclohexylphosphino-2'-(*N,N*-dimethylamino)biphenyl (0.026 g, 0.067 mmol) and sodium *tert*-butoxide (0.1 g, 1 mmol) in degassed 1,4-dioxan (3 ml) under argon was
- 10 heated in a microwave oven in a sealed vessel to 125 °C for 0.25 h. The cooled reaction mixture was filtered and the filtrate concentrated *in vacuo* to a residue, which was purified by chromatography over silica gel eluting with a gradient of acetone/toluene to give the title compound (D10) as an oil (0.188 g, 0.38 mmol, 51%).
- 15 δ_H (CDCl₃) 1.49 (9H, s), 2.93 (2H, t, J = 8.5Hz), 3.28-3.32 (4H, m), 3.70-3.74 (4H, m), 4.01 (2H, t, J = 8.6Hz), 6.94-7.28 (4H, m), 7.49-7.58 (2H, m), 7.72 (1H, d, J = 8.2Hz), 8.57 (1H, d, J = 2.3Hz), 9.15 (1H, d, J = 2.3Hz).
- Mass Spectrum: C₂₆H₃₀N₄O₄S requires 494; found 495 (MH⁺)


Description 11-13 (D11-D13)

- 20 Description 11-13 (D11-D13) were prepared as described in Description 10 using the respective intermediates (D7), (D8) and (D9).

Compound	Mol Form. (requires)	MS (MH ⁺)
1,1-Dimethylethyl 4-{3-[(5-fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-quinoliny]-1-piperazinecarboxylate (D11)	C ₂₆ H ₂₉ FN ₄ O ₄ S (512)	513
1,1-Dimethylethyl 4-[3-(1-piperidinylsulfonyl)-8-quinoliny]-1-piperazinecarboxylate (D12)	C ₂₃ H ₃₂ N ₄ O ₄ S (460)	461
1,1-Dimethylethyl 4-[3-(4-morpholinylsulfonyl)-8-quinoliny]-1-piperazinecarboxylate (D13)	C ₂₂ H ₃₀ N ₄ O ₅ S (462)	463

Example 1

- 25 **3-(2,3-Dihydro-1H-indol-1-ylsulfonyl)-8-(1-piperazinyl)quinoline hydrochloride (E1)**



A stirred solution of 1,1-dimethylethyl 4-[3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-8-quinoliny]-1-piperazinecarboxylate (D10) (0.188 g, 0.38 mmol) in 1,4-dioxan (3 ml) and

aqueous 4 M hydrochloric acid (3 ml) was heated at 80 °C for 1.5 h under argon. The reaction mixture was concentrated *in vacuo* and the residue was stirred with diethyl ether (5 ml) and the resulting solid collected by filtration to afford the title compound (E1) 0.122 g, 0.28 mmol, 74%).


5 δ_H (d_6 -DMSO) 2.89-2.96 (2H, m), 3.30 (4H, br, s), 3.54 (4H, br, s), 4.03-4.09 (2H, m), 6.99 (1H, dd, $J = 0.9\text{Hz}$, 7.4Hz), 7.14-7.26 (2H, m), 7.40 (1H, d, $J = 6.7\text{Hz}$), 7.57-7.69 (2H, m), 7.84 (1H, d, $J = 7.3\text{Hz}$), 8.98 (1H, d, $J = 2.4\text{Hz}$), 9.06 (1H, d, $J = 2.4\text{Hz}$), 9.30 (2H, br, s).

Mass Spectrum: $C_{21}H_{22}N_4O_2S$ requires 394; found 395 (MH^+)

10

Example 2

3-[(5-Fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-(1-piperazinyl)quinoline hydrochloride (E2)



15 The title compound (E2) was prepared from 1,1-dimethylethyl 4-{3-[(5-fluoro-2,3-dihydro-1H-isoindol-2-yl)sulfonyl]-8-quinoliny]-1-piperazinecarboxylate (D11) in a similar manner to that of Example 1, in 32% yield.


δ_H (d_6 -DMSO) 3.34 (4H, br, s), 3.55 (4H, br, s), 4.67-4.70 (4H, m), 6.96-7.10 (2H, m), 7.23-7.28 (1H, m), 7.40 (1H, d, $J = 6.9\text{Hz}$), 7.66 (1H, t, $J = 8.0\text{Hz}$), 7.85 (1H, d, $J = 7.8\text{Hz}$), 8.96 (1H, d, $J = 2.4\text{Hz}$), 9.10 (2H, br, s), 9.17 (1H, d, $J = 2.4\text{Hz}$).

20

Mass Spectrum: $C_{21}H_{21}FN_4O_2S$ requires 412; found 413 (MH^+)

Example 3

8-(1-Piperazinyl)-3-(1-piperidinylsulfonyl)quinoline hydrochloride (E3)



25

The title compound (E3) was prepared from 1,1-dimethylethyl 4-[3-(1-piperidinylsulfonyl)-8-quinoliny]-1-piperazinecarboxylate (D12) in a similar manner to that of Example 1, in 77% yield.


δ_H (d_6 -DMSO) 1.38 (2H, br, s), 1.56 (4H, br, s), 2.99-3.04 (4H, m), 3.35 (4H, br, s), 3.60 (4H, br, s), 7.42 (1H, d, $J = 6.8\text{Hz}$), 7.68 (1H, t, $J = 8.0\text{Hz}$), 7.87 (1H, d, $J = 7.4\text{Hz}$), 8.84 (1H, d, $J = 2.4\text{Hz}$), 9.05 (1H, d, $J = 2.4\text{Hz}$), 9.40 (2H, br, s).

Mass Spectrum: $C_{18}H_{24}N_4O_2S$ requires 360; found 361 (MH^+)

5

Example 4

3-(Morpholin-4-ylsulfonyl)-8-(1-piperazinyl)quinoline hydrochloride (E4)




The title compound (E4) was prepared from 1,1-dimethylethyl 4-[3-(4-morpholinylsulfonyl)-8-quinolinyl]-1-piperazinecarboxylate (D13) in a similar manner to that of Example 1, in 26% yield.

δ_H (d_6 -DMSO) 3.01 (4H, br, s), 3.40 (4H, br, s), 3.57-3.67 (8H, m), 7.44 (1H, d, $J = 6.6\text{Hz}$), 7.70 (1H, t, $J = 7.8\text{Hz}$), 7.88 (1H, d, $J = 7.3\text{Hz}$), 8.87 (1H, d, $J = 2.4\text{Hz}$), 9.06 (1H, d, $J = 2.4\text{Hz}$), 9.17 (2H, br, s).

Mass Spectrum: $C_{17}H_{22}N_4O_3S$ requires 362; found 363 (MH^+)

Example 5

3-(2,3-Dihydro-1H-indol-1-ylsulfonyl)-8-(4-methyl-1-piperazinyl)quinoline hydrochloride (E5)



3-(2,3-Dihydro-1H-indol-1-ylsulfonyl)-8-(1-piperazinyl)quinoline hydrochloride (E1) (0.080 g, 0.19 mmol) was first converted to the corresponding free base by dissolving in a 5% aqueous solution of sodium hydrogen carbonate (5 ml) and extracting the solution with dichloromethane (3 x 5 ml). The combined extracts were dried ($MgSO_4$) and concentrated *in vacuo* to an oil which was identified as the free base of (E1).

A 37% aqueous solution of formaldehyde (0.030 ml, 0.4 mmol) was added to a stirred solution of 3-(2,3-dihydro-1H-indol-1-ylsulfonyl)-8-(1-piperazinyl)quinoline (E1) (0.056 g, 0.14 mmol) in ethanol (5 ml) and acetic acid (0.1 ml) at ambient temperature. Sodium triacetoxyborohydride (0.11 g, 0.52 mmol) was added and the mixture was stirred under argon for 0.4 h. The reaction mixture was passed down an SCX chromatography

column eluting with a solution made up from concentrated aqueous ammonium hydroxide (specific gravity 0.88) and methanol (1:10^{vol/vol}). Column fractions containing only the required product were pooled and concentrated *in vacuo* to give an oil which was dissolved in methanol and treated with a 1M solution of hydrogen chloride in diethyl ether (1.1 molar equivalents). The solution was concentrated *in vacuo* and the residue was stirred with diethyl ether (2 ml) to give the title compound (E5) as a yellow solid (0.050 g, 0.12 mmol, 87%).


δ_H (d₆-DMSO) 2.85 (3H, d, J = 4.6Hz), 2.89-2.96 (2H, m), 3.14-3.40 (4H, m), 3.51-3.56 (2H, m), 3.96-4.13 (4H, m), 6.99 (1H, dd, J = 1Hz, 7.4Hz), 7.14 (1H, d, J = 6.5Hz), 7.23 (1H, t, J = 7.3Hz), 7.40 (1H, d, J = 6.6Hz), 7.57-7.69 (2H, m), 7.84 (1H, d, J = 7.3Hz), 9.0 (1H, d, J = 2.4Hz), 9.05 (1H, d, J = 2.4Hz), 10.6 (1H, Br, s).
Mass Spectrum: C₂₂H₂₄N₄O₂S requires 408; found 409 (MH⁺)

Pharmacological data

- 15 Compounds can be tested following the procedures outlined in WO98/27081.
The compounds of Examples E1-E5 were tested and showed good affinity for the 5-HT₆ receptor, having pK_i values ≥ 7.5 at human cloned 5-HT₆ receptors.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents hydrogen, C₁₋₆ alkyl, -C₀₋₄ alkyl-C₃₋₈cycloalkyl, -C₁₋₄ alkyl-aryl, -C₁₋₄ alkyl-heteroaryl or -C₀₋₄ alkyl-heterocyclyl;

wherein said alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R¹ may be optionally substituted by one or more (eg. 1, 2 or 3) halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl groups;

R² represents hydrogen or C₁₋₆ alkyl;

m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R² groups may instead be linked to form a CH₂, (CH₂)₂ or (CH₂)₃ group;

when R¹ represents C₁₋₆ alkyl, R¹ may optionally be linked to R² to form a group (CH₂)₂, (CH₂)₃ or (CH₂)₄;

R³, R⁴ and R⁵ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or R⁶ and R⁷ together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

n represents an integer from 1 to 3;

p represents 1 or 2;

R^a represents hydrogen, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₇cycloalkyl or -C₁₋₃alkyl-C₃₋₇cycloalkyl;

R^b represents hydrogen, C₁₋₆alkyl, -C₀₋₄alkyl-aryl or -C₀₋₄alkyl-heteroaryl;

or R^a and R^b together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl group;

wherein said aryl, heteroaryl or heterocyclyl groups of R^a and R^b may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or

different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy,

- arylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group CONR⁸R⁹ or SO₂NR⁸R⁹, wherein R⁸ and R⁹ independently represent hydrogen or C₁₋₆ alkyl or R⁸ and R⁹ together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group; or solvates thereof.
2. A compound of formula (I) as defined in claim 1 which is:
3-(2,3-Dihydro-1*H*-indol-1-ylsulfonyl)-8-(1-piperazinyl)quinoline;
3-[(5-Fluoro-2,3-dihydro-1*H*-isoindol-2-yl)sulfonyl]-8-(1-piperazinyl)quinoline;
8-(1-Piperazinyl)-3-(1-piperidinylsulfonyl)quinoline;
3-(Morpholin-4-ylsulfonyl)-8-(1-piperazinyl)quinoline; or
3-(2,3-Dihydro-1*H*-indol-1-ylsulfonyl)-8-(4-methyl-1-piperazinyl)quinoline;
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition which comprises a compound as defined in claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.
4. A compound as defined in claim 1 or claim 2 for use in therapy.
5. A compound as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
6. The use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.
8. A method of treating depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/009724

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/12 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/080608 A (JOHNSON CHRISTOPHER NORBERT ; MITCHELL DARREN JASON (GB); WITTY DAVID) 2 October 2003 (2003-10-02) the whole document	1-8
P,X	WO 03/080580 A (JOHNSON CHRISTOPHER NORBERT ; WADE CHARLES EDWARD (GB); AHMED MAHMOOD) 2 October 2003 (2003-10-02) the whole document	1-8
Y	WO 03/042208 A (BOETTCHER HENNING ; MERCK PATENT GMBH (DE); VAN AMSTERDAM CHRISTOPH (D) 22 May 2003 (2003-05-22) claim 6, compound 1f the whole document claims 1-17	1-8
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

20 December 2004

Date of mailing of the international search report

29/12/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Deutsch, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/009724

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2003/158202 A1 (JENSEN ANNIKA JENMALM ET AL) 21 August 2003 (2003-08-21) the whole document -----	1-8
Y	WO 01/32646 A (BROMIDGE STEVEN MARK ; SERAFINOWSKA HALINA TERESA (GB); SMITHKLINE BEE) 10 May 2001 (2001-05-10) the whole document -----	1-8
X	US 6 423 717 B1 (WYMAN PAUL ADRIAN ET AL) 23 July 2002 (2002-07-23) the whole document column 1, line 29 - column 2, line 19 -----	1-8

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/009724

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03080608	A	02-10-2003	WO 03080608 A2	02-10-2003
WO 03080580	A	02-10-2003	CA 2479786 A1	02-10-2003
			WO 03080580 A2	02-10-2003
WO 03042208	A	22-05-2003	BR 0214046 A	13-10-2004
			CA 2467081 A1	22-05-2003
			WO 03042208 A1	22-05-2003
			EP 1444229 A1	11-08-2004
US 2003158202	A1	21-08-2003	BR 0210291 A	13-07-2004
			CA 2445653 A1	19-12-2002
			EP 1412325 A1	28-04-2004
			WO 02100822 A1	19-12-2002
WO 0132646	A	10-05-2001	AU 1278701 A	14-05-2001
			WO 0132646 A2	10-05-2001
			EP 1228066 A2	07-08-2002
			JP 2003513085 T	08-04-2003
US 6423717	B1	23-07-2002	AT 247099 T	15-08-2003
			AU 729056 B2	25-01-2001
			AU 6090498 A	15-07-1998
			BG 103530 A	31-01-2000
			BR 9713734 A	28-03-2000
			CA 2275492 A1	25-06-1998
			CN 1246116 A	01-03-2000
			CZ 9902203 A3	17-11-1999
			DE 69724142 D1	18-09-2003
			DE 69724142 T2	03-06-2004
			EA 2351 B1	25-04-2002
			WO 9827081 A1	25-06-1998
			EP 0946539 A1	06-10-1999
			ES 2203831 T3	16-04-2004
			HU 0000658 A2	28-02-2001
			ID 22821 A	09-12-1999
			JP 2001506646 T	22-05-2001
			MA 24426 A1	01-07-1998
			NO 993003 A	18-06-1999
			NZ 335970 A	26-10-2001
			OA 11066 A	10-03-2003
			PL 334337 A1	28-02-2000
			SK 80899 A3	14-02-2000
			TR 9901361 T2	23-08-1999
			TW 418205 B	11-01-2001
			US 2003069233 A1	10-04-2003
			ZA 9711319 A	17-06-1999